美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · ANVS近 30 天 0 則 · 第 1 / 1 頁
- Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
- Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial
- Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
- Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
- Annovis Bio Regains NYSE Listing Compliance
- 3 Parkinson's Biotech Stocks Analysts Think Are Wildly Mispriced
- Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
- Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
- Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
- Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
- Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
- Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
- Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
- Annovis Publishes Historical Review of Buntanetap in The Scientist
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。